RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $135.6M Add to my watchlist

Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight

RCE UPDATE HIGHLIGHTS KEY DEVELOPMENTS FOR UPSIDE

Announcements

Filter Results

All Price Sensitive Only

RCE	Appendix 2A		21/05/20	39.78KB	Share
RCE	Corporate Presentation - May 2020		21/05/20	3.22MB	Share
RCE	Positive Data on RECCE 327 Against Neisseria gonorrhoeae	PRICE SENSITIVE	04/05/20	452.72KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/04/20	400.44KB	Share
RCE	Further Positive Data on RECCE 327 Against MRSA Superbug	PRICE SENSITIVE	23/04/20	875.14KB	Share
RCE	Positive Data on RECCE 327 Against Influenza A	PRICE SENSITIVE	20/04/20	573.09KB	Share
RCE	Trading Halt	PRICE SENSITIVE	16/04/20	272.42KB	Share
RCE	Recce Signs Phase I Human Clinical Trial Agreement	PRICE SENSITIVE	08/04/20	269.15KB	Share
RCE	First-in-Human Clinical Trial Progress Update	PRICE SENSITIVE	17/03/20	337.38KB	Share
RCE	Cleansing Statement		27/02/20	177.66KB	Share
RCE	Appendix 2A		27/02/20	323.8KB	Share
RCE	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	387.4KB	Share
RCE	Positive Efficacy Data in Kidney/UTI infections animal model	PRICE SENSITIVE	14/02/20	551.41KB	Share
RCE	Positive Data from RECCE 327 Antibiotic Safety Studies	PRICE SENSITIVE	10/02/20	966.57KB	Share
RCE	Appendix 4C and Commentary	PRICE SENSITIVE	31/01/20	883.85KB	Share
RCE	Cleansing Statement		16/01/20	177.89KB	Share
RCE	Appendix 2A		16/01/20	274.3KB	Share
RCE	Change of Director's Interest Notice		20/12/19	267.69KB	Share
RCE	Change of Director's Interest Notice		19/12/19	224.41KB	Share
RCE	Cleansing Statement		19/12/19	243.32KB	Share
RCE	Appendix 3B		19/12/19	113.31KB	Share
RCE	Corporate Presentation - December 2019		04/12/19	2.58MB	Share
RCE	Constitution		29/11/19	605.86KB	Share
RCE	Positive Data for RECCE 327 in MRSA Burns Wound Infection	PRICE SENSITIVE	27/11/19	712.48KB	Share
RCE	Results of Meeting		25/11/19	181.59KB	Share
RCE	Trading Halt	PRICE SENSITIVE	25/11/19	276.11KB	Share
RCE	Opening Address at 2019 World Antibiotic Resistance Congress		08/11/19	2.84MB	Share
RCE	Appendix 4C and Commentary	PRICE SENSITIVE	31/10/19	850.63KB	Share
RCE	Notice of Annual General Meeting/Proxy Form		25/10/19	1.65MB	Share
RCE	White Paper on Recce Synthetic Polymer Antibiotics		23/10/19	2.64MB	Share
RCE	Change in substantial holding		16/10/19	250.41KB	Share
RCE	Cleansing Statement		16/10/19	211.16KB	Share
RCE	Notice under ASX Listing Rule 3.10.5A		16/10/19	186.03KB	Share
RCE	Appendix 3B		16/10/19	397.59KB	Share
RCE	Recce Completes Raising of $6.76 million	PRICE SENSITIVE	10/10/19	244.08KB	Share
RCE	Trading Halt	PRICE SENSITIVE	08/10/19	421.91KB	Share
RCE	Results of Meeting		30/09/19	179.22KB	Share
RCE	Appendix 4G		27/09/19	145.28KB	Share
RCE	2019 Annual Report		27/09/19	11.56MB	Share
RCE	Key Family 2 Patent Granted in Japan for RECCE Antibiotics	PRICE SENSITIVE	20/09/19	238.51KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	18/09/19	273.07KB	Share
RCE	Funding Update	PRICE SENSITIVE	11/09/19	240.9KB	Share
RCE	Investor Presentation - September 2019		10/09/19	4.03MB	Share
RCE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	30/08/19	310.09KB	Share
RCE	Notice of General Meeting/Proxy Form		30/08/19	1.54MB	Share
RCE	Government Grant for University and Industry Collaboration		30/08/19	249.41KB	Share
RCE	FDA Positive Response for Recce Scaled Manufacture & Quality	PRICE SENSITIVE	26/08/19	253.13KB	Share
RCE	Response to ASX Appendix 4C Query	PRICE SENSITIVE	16/08/19	745.16KB	Share
RCE	Change of Director's Interest Notice		14/08/19	372.09KB	Share
RCE	Change of Director's Interest Notice		08/08/19	224.49KB	Share
RCE	Key Family 2 Patent Granted in Europe for RECCE Antibiotics	PRICE SENSITIVE	08/08/19	239.06KB	Share
RCE	Opening R&D Address at World Antibiotic Resistance Congress	PRICE SENSITIVE	01/08/19	570.79KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	30/07/19	767.78KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	30/07/19	170.61KB	Share
RCE	Initial Director's Interest Notice		12/07/19	156.32KB	Share
RCE	Appointment of Independent Chair and Additional Director	PRICE SENSITIVE	09/07/19	280.92KB	Share
RCE	Leading Physician to Chair Clinical Advisory Committee		03/06/19	217.64KB	Share
RCE	R&D Incentive Rebate Received		01/05/19	241.11KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	29/04/19	487.15KB	Share
RCE	Investor Presentation - April 2019		10/04/19	2.4MB	Share
RCE	USA Patent Granted for Recce's Antibiotics	PRICE SENSITIVE	14/03/19	213.86KB	Share
RCE	Change of Director's Interest Notice		07/03/19	359.01KB	Share
RCE	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/19	363.14KB	Share
RCE	Change in substantial holding		15/02/19	306.38KB	Share
RCE	Change of Director's Interest Notice		15/02/19	222.36KB	Share
RCE	Cleansing Statement		15/02/19	234.66KB	Share
RCE	Notice under ASX Listing Rule 3.10.5A		15/02/19	219.65KB	Share
RCE	Issue of Securities and Appendix 3B		15/02/19	473.94KB	Share
RCE	Recce Successfully Raises $1.8 million via Placement	PRICE SENSITIVE	08/02/19	296.72KB	Share
RCE	Trading Halt	PRICE SENSITIVE	06/02/19	272.95KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	31/01/19	672.92KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	31/01/19	218.33KB	Share
RCE	Funding Update	PRICE SENSITIVE	18/01/19	205.25KB	Share
RCE	Funding Update		16/01/19	202.72KB	Share
RCE	Funding Update	PRICE SENSITIVE	18/12/18	203.36KB	Share
RCE	Company Constitution		03/12/18	583.36KB	Share
RCE	Results of Meeting		29/11/18	271.94KB	Share
RCE	Funding Update	PRICE SENSITIVE	23/11/18	261.78KB	Share
RCE	Investor Presentation		21/11/18	4.59MB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	01/11/18	336.62KB	Share
RCE	Notice of General Meeting/Proxy Form		29/10/18	1.29MB	Share
RCE	Recce Meets Antibiotic Leaders to Explore Opportunities		25/10/18	1.95MB	Share
RCE	Date of 2018 Annual General Meeting		08/10/18	118.09KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	02/10/18	355.26KB	Share
RCE	Appendix 4G		28/09/18	100.09KB	Share
RCE	2018 Annual Report		28/09/18	7.41MB	Share
RCE	Change of Registry Address: Automic P/L - Sydney Office		28/09/18	91.41KB	Share
RCE	Funding Update	PRICE SENSITIVE	13/09/18	191.19KB	Share
RCE	Investor Presentation		12/09/18	1.22MB	Share
RCE	Investor Presentation		04/09/18	1.14MB	Share
RCE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	31/08/18	254.44KB	Share
RCE	Key Australian Patent for Recce's Broad-Spectrum Antibiotics	PRICE SENSITIVE	31/07/18	427.82KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	30/07/18	968.99KB	Share
RCE	Update on Progress of Broad Spectrum Antibiotic RECCE 327	PRICE SENSITIVE	17/07/18	180.48KB	Share
RCE	Change of Share Registry		16/07/18	118.78KB	Share
RCE	Recce Presented at FNN/Shaw and Partners Investor Conference		21/06/18	321.34KB	Share
RCE	Update on meeting with US FDA	PRICE SENSITIVE	05/06/18	520.35KB	Share
RCE	Investor Presentation		05/06/18	2.3MB	Share
RCE	Recce Pharmaceuticals to Present at Investor Conference		30/05/18	135.61KB	Share
RCE	Update on meeting with US FDA		16/05/18	182.04KB	Share

RCE Appendix 2A
21/05/20		39.78KB	Share
RCE Corporate Presentation - May 2020
21/05/20		3.22MB	Share
RCE Positive Data on RECCE 327 Against Neisseria gonorrhoeae
04/05/20	PRICE SENSITIVE	452.72KB	Share
RCE Appendix 4C and Activity Report
29/04/20	PRICE SENSITIVE	400.44KB	Share
RCE Further Positive Data on RECCE 327 Against MRSA Superbug
23/04/20	PRICE SENSITIVE	875.14KB	Share
RCE Positive Data on RECCE 327 Against Influenza A
20/04/20	PRICE SENSITIVE	573.09KB	Share
RCE Trading Halt
16/04/20	PRICE SENSITIVE	272.42KB	Share
RCE Recce Signs Phase I Human Clinical Trial Agreement
08/04/20	PRICE SENSITIVE	269.15KB	Share
RCE First-in-Human Clinical Trial Progress Update
17/03/20	PRICE SENSITIVE	337.38KB	Share
RCE Cleansing Statement
27/02/20		177.66KB	Share
RCE Appendix 2A
27/02/20		323.8KB	Share
RCE Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	387.4KB	Share
RCE Positive Efficacy Data in Kidney/UTI infections animal model
14/02/20	PRICE SENSITIVE	551.41KB	Share
RCE Positive Data from RECCE 327 Antibiotic Safety Studies
10/02/20	PRICE SENSITIVE	966.57KB	Share
RCE Appendix 4C and Commentary
31/01/20	PRICE SENSITIVE	883.85KB	Share
RCE Cleansing Statement
16/01/20		177.89KB	Share
RCE Appendix 2A
16/01/20		274.3KB	Share
RCE Change of Director's Interest Notice
20/12/19		267.69KB	Share
RCE Change of Director's Interest Notice
19/12/19		224.41KB	Share
RCE Cleansing Statement
19/12/19		243.32KB	Share
RCE Appendix 3B
19/12/19		113.31KB	Share
RCE Corporate Presentation - December 2019
04/12/19		2.58MB	Share
RCE Constitution
29/11/19		605.86KB	Share
RCE Positive Data for RECCE 327 in MRSA Burns Wound Infection
27/11/19	PRICE SENSITIVE	712.48KB	Share
RCE Results of Meeting
25/11/19		181.59KB	Share
RCE Trading Halt
25/11/19	PRICE SENSITIVE	276.11KB	Share
RCE Opening Address at 2019 World Antibiotic Resistance Congress
08/11/19		2.84MB	Share
RCE Appendix 4C and Commentary
31/10/19	PRICE SENSITIVE	850.63KB	Share
RCE Notice of Annual General Meeting/Proxy Form
25/10/19		1.65MB	Share
RCE White Paper on Recce Synthetic Polymer Antibiotics
23/10/19		2.64MB	Share
RCE Change in substantial holding
16/10/19		250.41KB	Share
RCE Cleansing Statement
16/10/19		211.16KB	Share
RCE Notice under ASX Listing Rule 3.10.5A
16/10/19		186.03KB	Share
RCE Appendix 3B
16/10/19		397.59KB	Share
RCE Recce Completes Raising of $6.76 million
10/10/19	PRICE SENSITIVE	244.08KB	Share
RCE Trading Halt
08/10/19	PRICE SENSITIVE	421.91KB	Share
RCE Results of Meeting
30/09/19		179.22KB	Share
RCE Appendix 4G
27/09/19		145.28KB	Share
RCE 2019 Annual Report
27/09/19		11.56MB	Share
RCE Key Family 2 Patent Granted in Japan for RECCE Antibiotics
20/09/19	PRICE SENSITIVE	238.51KB	Share
RCE R&D Incentive Rebate Received
18/09/19	PRICE SENSITIVE	273.07KB	Share
RCE Funding Update
11/09/19	PRICE SENSITIVE	240.9KB	Share
RCE Investor Presentation - September 2019
10/09/19		4.03MB	Share
RCE Appendix 4E - Preliminary Final Report
30/08/19	PRICE SENSITIVE	310.09KB	Share
RCE Notice of General Meeting/Proxy Form
30/08/19		1.54MB	Share
RCE Government Grant for University and Industry Collaboration
30/08/19		249.41KB	Share
RCE FDA Positive Response for Recce Scaled Manufacture & Quality
26/08/19	PRICE SENSITIVE	253.13KB	Share
RCE Response to ASX Appendix 4C Query
16/08/19	PRICE SENSITIVE	745.16KB	Share
RCE Change of Director's Interest Notice
14/08/19		372.09KB	Share
RCE Change of Director's Interest Notice
08/08/19		224.49KB	Share
RCE Key Family 2 Patent Granted in Europe for RECCE Antibiotics
08/08/19	PRICE SENSITIVE	239.06KB	Share
RCE Opening R&D Address at World Antibiotic Resistance Congress
01/08/19	PRICE SENSITIVE	570.79KB	Share
RCE Appendix 4C and commentary
30/07/19	PRICE SENSITIVE	767.78KB	Share
RCE R&D Incentive Rebate Received
30/07/19	PRICE SENSITIVE	170.61KB	Share
RCE Initial Director's Interest Notice
12/07/19		156.32KB	Share
RCE Appointment of Independent Chair and Additional Director
09/07/19	PRICE SENSITIVE	280.92KB	Share
RCE Leading Physician to Chair Clinical Advisory Committee
03/06/19		217.64KB	Share
RCE R&D Incentive Rebate Received
01/05/19		241.11KB	Share
RCE Appendix 4C and commentary
29/04/19	PRICE SENSITIVE	487.15KB	Share
RCE Investor Presentation - April 2019
10/04/19		2.4MB	Share
RCE USA Patent Granted for Recce's Antibiotics
14/03/19	PRICE SENSITIVE	213.86KB	Share
RCE Change of Director's Interest Notice
07/03/19		359.01KB	Share
RCE Half Yearly Report and Accounts
27/02/19	PRICE SENSITIVE	363.14KB	Share
RCE Change in substantial holding
15/02/19		306.38KB	Share
RCE Change of Director's Interest Notice
15/02/19		222.36KB	Share
RCE Cleansing Statement
15/02/19		234.66KB	Share
RCE Notice under ASX Listing Rule 3.10.5A
15/02/19		219.65KB	Share
RCE Issue of Securities and Appendix 3B
15/02/19		473.94KB	Share
RCE Recce Successfully Raises $1.8 million via Placement
08/02/19	PRICE SENSITIVE	296.72KB	Share
RCE Trading Halt
06/02/19	PRICE SENSITIVE	272.95KB	Share
RCE Appendix 4C and commentary
31/01/19	PRICE SENSITIVE	672.92KB	Share
RCE R&D Incentive Rebate Received
31/01/19	PRICE SENSITIVE	218.33KB	Share
RCE Funding Update
18/01/19	PRICE SENSITIVE	205.25KB	Share
RCE Funding Update
16/01/19		202.72KB	Share
RCE Funding Update
18/12/18	PRICE SENSITIVE	203.36KB	Share
RCE Company Constitution
03/12/18		583.36KB	Share
RCE Results of Meeting
29/11/18		271.94KB	Share
RCE Funding Update
23/11/18	PRICE SENSITIVE	261.78KB	Share
RCE Investor Presentation
21/11/18		4.59MB	Share
RCE Appendix 4C and commentary
01/11/18	PRICE SENSITIVE	336.62KB	Share
RCE Notice of General Meeting/Proxy Form
29/10/18		1.29MB	Share
RCE Recce Meets Antibiotic Leaders to Explore Opportunities
25/10/18		1.95MB	Share
RCE Date of 2018 Annual General Meeting
08/10/18		118.09KB	Share
RCE R&D Incentive Rebate Received
02/10/18	PRICE SENSITIVE	355.26KB	Share
RCE Appendix 4G
28/09/18		100.09KB	Share
RCE 2018 Annual Report
28/09/18		7.41MB	Share
RCE Change of Registry Address: Automic P/L - Sydney Office
28/09/18		91.41KB	Share
RCE Funding Update
13/09/18	PRICE SENSITIVE	191.19KB	Share
RCE Investor Presentation
12/09/18		1.22MB	Share
RCE Investor Presentation
04/09/18		1.14MB	Share
RCE Appendix 4E - Preliminary Final Report
31/08/18	PRICE SENSITIVE	254.44KB	Share
RCE Key Australian Patent for Recce's Broad-Spectrum Antibiotics
31/07/18	PRICE SENSITIVE	427.82KB	Share
RCE Appendix 4C and commentary
30/07/18	PRICE SENSITIVE	968.99KB	Share
RCE Update on Progress of Broad Spectrum Antibiotic RECCE 327
17/07/18	PRICE SENSITIVE	180.48KB	Share
RCE Change of Share Registry
16/07/18		118.78KB	Share
RCE Recce Presented at FNN/Shaw and Partners Investor Conference
21/06/18		321.34KB	Share
RCE Update on meeting with US FDA
05/06/18	PRICE SENSITIVE	520.35KB	Share
RCE Investor Presentation
05/06/18		2.3MB	Share
RCE Recce Pharmaceuticals to Present at Investor Conference
30/05/18		135.61KB	Share
RCE Update on meeting with US FDA
16/05/18		182.04KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 66.5¢		Change 0.000(0.00%)		Mkt cap ! $135.6M

Open	High	Low	Value	Volume
66.5¢	66.5¢	65.0¢	$23.95K	36.19K

Buyers (Bids)

No.	Vol.	Price($)
1	16765	66.5¢

Sellers (Offers)

Price($)	Vol.	No.
67.0¢	74000	4

View Market Depth

No.	Vol.	Price($)
1	16765	0.665
1	25000	0.640
1	24674	0.635
1	12099	0.610
6	14402	0.600

Price($)	Vol.	No.
0.670	74000	4
0.675	50000	1
0.680	28537	3
0.690	61200	2
0.695	52037	2

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 66.5¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
66.5¢	66.5¢	66.5¢	411
Last updated 15.06pm 08/05/2024 ?

RCE (ASX) Chart

RECCE PHARMACEUTICALS LTD - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories